GV returned for a series C round that helped the precision cancer medicine developer increase its overall funding to over $180m.
FogPharma, a US-based cancer precision medicine developer received $107m on Wednesday in a series C round featuring GV, a corporate venturing subsidiary of internet and technology group Alphabet. The round was led by life sciences investment firm VenBio Partners and included 6 Dimensions Capital, an investment firm co-founded by pharmaceutical firm WuXi AppTec. Cormorant Asset…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
